Dr. Aditi Singh

Thoracic, Head and Neck Oncologist @VAMinneapolis, assistant professor of medicine @UMNews, thoracic Fellow @Mayocancercare, MPH @JohnsHopkinsSPH

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

New clinical trial now open 🧪🫁
Alliance A082402 is studying if targeted post op radiation (I² PORT) can reduce recurrence in high risk #NSCLC patients after surgery while limiting side effects. Learn more https://t.co/UG6XLyzBgu. #LungCancer #ClinicalTrials #RadiationTherapy

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

Now recruiting! @BradMcG04 of @DanaFarber leads @ALLIANCE_org
A032201 (STRIKE) to see if adding the anti-cancer drug tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://t.co/BN81H5OBQ2 #NCI

[Dr. Aditi Singh @pulmoncdoc]

@AHazimMD @KLeventakos @aadel_chaudhuri Best of Luck

[JTO & JTO CRR @JTOonline]

Carbone et al. showed that mesothelioma in patients with the BAP1+/- mutation is biologically, histologically, and clinically distinct, requiring a tailored treatment approach.

Read more in this month's JTO: https://t.co/0DvkblDcnN

[Alliance for Clinical Trials in Oncology @ALLIANCE_org]

A082101 led @AMansfieldMD of @MayoClinic evaluates the safety & effectiveness of immunotherapy before surgery for #mesothelioma. #Immunotherapy helps the body’s immune system fight cancer. Learn more: https://t.co/a8IpbGHcvZ @thenci #nctn

[Dr. Aditi Singh @pulmoncdoc]

@BalazsHalmosMD 😅

[Dr. Aditi Singh @pulmoncdoc]

@BalazsHalmosMD Yay

[Stephen V Liu, MD @StephenVLiu]

Does immunotherapy in #SCLC delay brain metastases? Retrospective report @LungCaJournal on 550 pts show pts treated with atezolizumab + carbo/etop longer time to intracranial progression: 24.4 vs 14.3m and if no PCI: 27.2 vs 15.2m. Improved PFS and OS.

https://t.co/sQPb3H878i

[Stephen V Liu, MD @StephenVLiu]

Report on NGS in squamous NSCLC @LungCaJournal from Dr. @Joshua_Reuss et al. Detected actionable genomic alterations in 22.2% of patients with squamous NSCLC and no history of smoking including #EGFR and #MET. In those with prior smoking, AGAs in 2.4%.

https://t.co/O9NQj5J4jJ

[Thor Halfdanarson @OncoThor]

https://t.co/GcjLjQcqPY

[Thor Halfdanarson @OncoThor]

Hot off the press, Alliance CABINET! Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs. The primary endpoint, PFS, was significantly better in the cabo arm than placebo.
@ALLIANCE_org

https://t.co/SszzXivMps

[Marie Suga, MD @jmsuga]

Do we need to do cardiac monitoring for all patients on Osimertinib?
Congrats to Dr Francisco Martinez, recent KPSF fellowship graduate’s poster at #wclc2024
Bottom line: >800 pts, 3700 ECHOs, only 10 Osi HF events
Higher in a fib, CHF hx pts
@KPDOR @Rayliukpsfo @LoriSakoda

[Dr. Aditi Singh @pulmoncdoc]

@DrSteveMartin @ececalidaylan Next Stop: Minneapolis! Last day to attend MN State Fair as well. You are missing on cheese curds and deep fried ranch.

[Katsuaki Maehara 🇯🇵 @KatsuakiMaehara]

🫁 Lung Cancer - ICIs data 🫁

🌟 Summary of 5-year (long follow-up) data

🌟 NSCLC (NSQ & SQ)

#Immunotherapy
#Lungcancer
#longfollowup
#LCSM

[Only In Boston @OnlyInBOS]

Make Way for the Celtics.

💚

[Dr. Aditi Singh @pulmoncdoc]

@KLeventakos Are you finally spilling the “olives” about your fitness?

[Kostas Leventakos @KLeventakos]

Diets | New England Journal of Medicine https://t.co/FPf7G237Xe
Excellent paper on diets. Robust evidence for Mediterranean diet benefits🫒

[soria @jsoriamd]

EGFR mutants are not a monolithic entity. In fact EGFR mutational status is heterogeneous and EGFR mutated cancers can be Dr Jekyll or Mr Hyde #AACR24 @marinagarassino

[soria @jsoriamd]

#ASCO24 environmental signatures in non-smoking lung cancer in Asia

[Jennifer A. Marks, MD @jennifermarksmd]

Management of pregnancy w/ 🫁ca
🚫 1st trimester
✅Dose according to actual body weight
✅Maintain dose intensity
🚫increase/decrease the dose
🚫chemotherapy @ 35-37 of gestation
✅minimum 3-week interval between the last cycle➡️delivery
🚫avoid IO in 2/3 trim
👀🫁-@matteolambe @asco #ASCO24 #lcsm